Literature DB >> 29171000

Applying pharmacokinetic/pharmacodynamic principles for optimizing antimicrobial therapy during continuous renal replacement therapy

Patrick M Honore1, Rita Jacobs, Elisabeth De Waele, Herbert D Spapen.   

Abstract

Continuous renal replacement therapy (CRRT) is progressively supplanting intermittent haemodialysis (IHD) in critically ill patients. Although CRRT indeed offers more appropriate haemodynamic, fluid, and metabolic stability, concern is rising about its impact on concomitant drugs and, in particular, antimicrobial treatment. Antimicrobial dose recommendations have been elaborated to avoid drug accumulation and toxicity in patients undergoing IHD. However, these dosing regimens have resulted in significant underdosing in patients undergoing CRRT, thereby increasing the risk of treatment failure and development of resistance. Applying pharmacokinetic/pharmacodynamic (PK/PD) principles may aid one to obtain more adequate antimicrobial therapy during CRRT. Much progress has been made in recent years resulting in relevant changes in particular antimicrobial therapies. In this review, we discuss antimicrobials that are frequently used in an intensive care setting. Drugs are divided according to their PK/PD characteristics and, wherever possible, dose recommendations during CRRT are provided. Of course, while therapeutic drug monitoring remains the best way to cope with PK/PD variability within a critically ill CRRT population, its bedside use is actually limited to some specific antibiotics.

Entities:  

Keywords:  antibiotics; antifungals; continuous; pharmacokinetics/pharmacodynamics; renal replacement therapy

Mesh:

Substances:

Year:  2017        PMID: 29171000     DOI: 10.5603/AIT.a2017.0071

Source DB:  PubMed          Journal:  Anaesthesiol Intensive Ther        ISSN: 1642-5758


  5 in total

1.  What a Clinician Should Know About a Renal Replacement Membrane?

Authors:  Patrick M Honore; Herbert D Spapen
Journal:  J Transl Int Med       Date:  2018-06-26

2.  Treatment of Ventilator-associated Pneumonia with High-dose Colistin Under Continuous Veno-venous Hemofiltration.

Authors:  Herbert Spapen; Johan van Laethem; Maya Hites; An Verdoodt; Marc Diltoer; Patrick M Honoré
Journal:  J Transl Int Med       Date:  2019-10-12

3.  500 mg as bolus followed by an extended infusion of 1500 mg of meropenem every 8 h failed to achieve in one-third of the patients an optimal PK/PD against non-resistant strains of these organisms: is CRRT responsible for this situation?

Authors:  Patrick M Honore; Leonel Barret Gutierrez; Luc Kugener; Sebastien Redant; Rachid Attou; Andrea Gallerani; David De Bels
Journal:  Ann Intensive Care       Date:  2020-12-03       Impact factor: 6.925

4.  Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant Acinetobacter baumannii Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration.

Authors:  Emir Kobic; Yasmeen Abouelhassan; Kumara Singaravelu; David P Nicolau
Journal:  Open Forum Infect Dis       Date:  2022-09-21       Impact factor: 4.423

Review 5.  [Pharmaceutical care for severe and critically ill patients with COVID-19].

Authors:  Saiping Jiang; Lu Li; Renping Ru; Chunhong Zhang; Yuefeng Rao; Bin Lin; Rongrong Wang; Na Chen; Xiaojuan Wang; Hongliu Cai; Jifang Sheng; Jianying Zhou; Xiaoyang Lu; Yunqing Qiu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.